HEMATOPOETİK KÖK HÜCRE NAKLİ
Kaynaklar:
1-Ayers EC, Li S, Medeiros LJ, et al. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. Cancer. 2020 Jan 15. 126 (2):293-303.
2-Nakasone H, Kanda Y, Ueda T, Matsumoto K, Shimizu N, Minami J, et al. Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma. Am J Hematol. 2009 Dec. 84(12):809-14.
3-Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006 Apr 27. 354(17):1813-26.
4-Laport GG, Alvarnas JC, Palmer JM, Snyder DS, Slovak ML, Cherry AM, et al. Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. Blood. 2008 Aug 1. 112(3):903-9.
5-Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012 Oct 18. 367(16):1487-96.
6-Wagner JE, Ishida-Yamamoto A, McGrath JA, et al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med. 2010 Aug 12. 363(7):629-39.
7-NCCN Clinical Practice Guidelines in Oncology. Pediatric Acute Lymphoblastic Leukemia. National Comprehensive Cancer Network. Available at https://www.nccn.org/professionals/physician_gls/pdf/ped_all.pdf. Version 2.2021 — October 22, 2020; Accessed: April 20, 2021.
8-Chronic Myelogenous Leukemia Treatment (PDQ®)–Health Professional Version. National Cancer Institute. Available at https://www.cancer.gov/types/leukemia/hp/cml-treatment-pdq#_418. March 5, 2021; Accessed: April 14, 2021.
9-Van Den Neste E, Casasnovas O, André M, Touati M, Senecal D, Edeline V, et al. Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant. Haematologica. 2013 Aug. 98 (8):1185-95.
10-Shah N, Callander N, Ganguly S, et al. Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015 Jul. 21 (7):1155-66.
11-Parody R, Martino R, de la Cámara R, et al. Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: improving outcomes over time. Bone Marrow Transplant. 2015 Feb. 50 (2):274-81.
12-Aprili G, Bosi A, Lombardini L, Pupella S, Vassanelli A, Italian Society of Transfusion Medicine and Immunohaematology., et al. Recommendations for managing the donation of haematopoietic stem cells from related and unrelated donors for allogeneic transplantation. Blood Transfus. 2013 Apr. 11 (2):296-304.
13-Carpenter PA, Englund JA. How I vaccinate blood and marrow transplant recipients. Blood. 2016 Jun 9. 127 (23):2824-32
14-Miano M, Faraci M, Dini G, Bordigoni P. Early complications following haematopoietic SCT in children. Bone Marrow Transplant. 2008 Jun. 41 Suppl 2:S39-42.
15-Couriel D, Caldera H, Champlin R, Komanduri K. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer. 2004 Nov 1. 101(9):1936-46.
16-Iwasaki T. Recent advances in the treatment of graft-versus-host disease. Clin Med Res. 2004 Nov. 2(4):243-52.
17-Shimabukuro-Vornhagen A, Glossmann J, Liebig T, Scheid C, von Bergwelt-Baildon M. The use of statins in hematopoietic stem cell transplantation. Curr Stem Cell Res Ther. 2009 Dec. 4(4):260-5
18-Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016
19-Laskin BL, Goebel J, Davies SM, Jodele S. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood. 2011 Aug 11. 118(6):1452-62.
20-Cabello-Kindelan C, Mackey S, Bayer AL. Adoptive T Regulatory Cell Therapy for Tolerance Induction. Curr Transplant Rep. 2015 Jun 1. 2 (2):191-201.
21-Wolf D, von Lilienfeld-Toal M, Wolf AM, et al. Novel treatment concepts for graft-versus-host disease. Blood. 2012 Jan 5. 119(1):16-25.
22-Porter DL. Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies. Hematology Am Soc Hematol Educ Program. 2011. 2011:292-8.
